Literature DB >> 11600480

The hepatorenal syndrome.

L Dagher1, K Moore.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11600480      PMCID： PMC1728492          DOI： 10.1136/gut.49.5.729

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  118 in total

1.  Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease.

Authors:  M H Koppel; J W Coburn; M M Mims; H Goldstein; J D Boyle; M E Rubini
Journal:  N Engl J Med       Date:  1969-06-19       Impact factor: 91.245

2.  N-acetylcysteine prevents development of the hyperdynamic circulation in the portal hypertensive rat.

Authors:  B Fernando; R Marley; S Holt; R Anand; D Harry; P Sanderson; R Smith; G Hamilton; K Moore
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

3.  Increased production of cysteinyl leukotrienes in hepatorenal syndrome.

Authors:  K P Moore; G W Taylor; N H Maltby; D Siegers; R W Fuller; C T Dollery; R Williams
Journal:  J Hepatol       Date:  1990-09       Impact factor: 25.083

4.  Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis.

Authors:  N Sheron; G Bird; J Goka; G Alexander; R Williams
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

5.  Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.

Authors:  J Saló; A Ginès; J C Quer; G Fernández-Esparrach; M Guevara; P Ginès; R Bataller; R Planas; W Jiménez; V Arroyo; J Rodés
Journal:  J Hepatol       Date:  1996-12       Impact factor: 25.083

6.  Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome.

Authors:  A Hadengue; A Gadano; R Moreau; E Giostra; F Durand; D Valla; S Erlinger; D Lebrec
Journal:  J Hepatol       Date:  1998-10       Impact factor: 25.083

7.  Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats.

Authors:  F Y Lee; L A Colombato; A Albillos; R J Groszmann
Journal:  Gastroenterology       Date:  1993-11       Impact factor: 22.682

8.  Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease.

Authors:  R D Zipser; J C Hoefs; P F Speckart; P K Zia; R Horton
Journal:  J Clin Endocrinol Metab       Date:  1979-06       Impact factor: 5.958

9.  Kidney, lower limb and whole-body uptake and release of catecholamines in alcoholic liver disease.

Authors:  J H Henriksen; H Ring-Larsen; N J Christensen
Journal:  Clin Physiol       Date:  1988-06

10.  Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis.

Authors:  D G Bichet; V J Van Putten; R W Schrier
Journal:  N Engl J Med       Date:  1982-12-16       Impact factor: 91.245
View more
  22 in total

1.  Fractional excretion of urea: A simple tool for the differential diagnosis of acute kidney injury in cirrhosis.

Authors:  Kavish R Patidar; Le Kang; Jasmohan S Bajaj; Daniel Carl; Arun J Sanyal
Journal:  Hepatology       Date:  2018-05-17       Impact factor: 17.425

Review 2.  Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Authors:  Elaine Yeung; Elaine Yong; Florence Wong
Journal:  MedGenMed       Date:  2004-12-02

Review 3.  Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.

Authors:  Francesco Salerno; Alexander Gerbes; Pere Ginès; Florence Wong; Vicente Arroyo
Journal:  Gut       Date:  2007-03-27       Impact factor: 23.059

Review 4.  Hepatorenal syndrome.

Authors:  Sharon Turban; Paul J Thuluvath; Mohamed G Atta
Journal:  World J Gastroenterol       Date:  2007-08-14       Impact factor: 5.742

Review 5.  [Renal insufficiency in patients with hepatic insufficiency].

Authors:  K Lenz; M Binder; R Buder; A Gruber; B Gutschreiter; M Voglmayr
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-26       Impact factor: 0.840

Review 6.  The management of patients awaiting liver transplantation.

Authors:  Ka-Kit Li; James Neuberger
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-10-06       Impact factor: 46.802

7.  Role of the cytochrome P-450/ epoxyeicosatrienoic acids pathway in the pathogenesis of renal dysfunction in cirrhosis.

Authors:  Michael M Yeboah; Md Abdul Hye Khan; Marla A Chesnik; Melissa Skibba; Lauren L Kolb; John D Imig
Journal:  Nephrol Dial Transplant       Date:  2018-08-01       Impact factor: 5.992

Review 8.  Management of hepatorenal syndrome.

Authors:  Halit Ziya Dundar; Tuncay Yılmazlar
Journal:  World J Nephrol       Date:  2015-05-06

9.  Pathogenetic background for treatment of ascites and hepatorenal syndrome.

Authors:  Søren Møller; Jens H Henriksen; Flemming Bendtsen
Journal:  Hepatol Int       Date:  2008-09-20       Impact factor: 6.047

10.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

Authors:  Arun J Sanyal; Thomas Boyer; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Andres Blei; Veit Gülberg; Samuel Sigal; Peter Teuber
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.